Navigation Links
Stemline Therapeutics Appoints Kevin Buchi, Former CEO of Cephalon, to Its Board of Directors
Date:3/15/2012

NEW YORK, March 15, 2012 /PRNewswire/ -- Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oncology therapeutics that target both cancer stem cells (CSCs) and tumor bulk, today announced that Kevin Buchi has joined its Board of Directors.

Since serving as Chief Executive Officer of Cephalon, Inc. through its $6.8 billion acquisition by Teva Pharmaceutical Industries (Nasdaq: TEVA) in October 2011, Mr. Buchi has served as Corporate Vice President, Global Branded Products for Teva. Mr. Buchi joined Cephalon in 1991 and held various positions, including Chief Operating Officer and Chief Financial Officer before becoming Cephalon's CEO in December 2010.

Ivan Bergstein, MD, Stemline's Chief Executive Officer, said, "We are honored to welcome Mr. Buchi to our Board of Directors. Kevin's vast experience and proven track record of success in this industry will be a tremendous asset to Stemline moving forward."

Mr. Buchi commented, "I am delighted to join Stemline's Board of Directors. The management team has done an outstanding job building out a clinical stage pipeline in an innovative area of oncology. I look forward to working with them as they advance these programs into late stage development and potentially into the marketplace."

About Stemline Therapeutics, Inc.

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company developing novel oncology therapeutics that target both cancer stem cells (CSCs) as well as the tumor bulk. Among Stemline's drug candidates are SL-401 and SL-701, both of which have demonstrated single agent clinical activity in Phase I/II studies of advanced cancer patients. In a multicenter Phase I/II trial in patients with advanced acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), SL-401 demonstrated single agent activity, including durable c
'/>"/>

SOURCE Stemline Therapeutics, Inc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Stemline Therapeutics Expands Clinical Oncology Program Directed at Cancer Stem Cells With Addition of M.D. Anderson Cancer Center
2. Stemline Therapeutics, Inc. Names Eric K. Rowinsky, M.D. Chief Medical Officer and Head of Research and Development
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
8. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... 2015 Research and Markets ( ... "Radiation Dose Management Market by Product (Dose ... Application (Computed Tomography, Angiography, Fluoroscopy), by End User ... report to their offering. The ... grow at a CAGR of around 50% during ...
(Date:5/5/2015)... , May 5, 2015  American Laboratory Trading, ... in North America, has named industry veteran Anggie Becorest ... Development. Becorest will be based out of the company,s ... role will include expanding the company,s west coast operations, ... opportunities. "ALT has been the leader in ...
(Date:5/5/2015)... Calif., May 5, 2015 Isis Pharmaceuticals, Inc. ... income of $4.0 million for the three months ended ... operating loss of $22.6 million for the same period ... to higher revenue from milestone payments earned from its ... a GAAP basis, Isis reported a loss from operations ...
Breaking Medicine Technology:Radiation Dose Management (Dose Tracking, Monitoring, and Analytics Software, Consulting Services) Market - Global Forecasts to 2020 2Radiation Dose Management (Dose Tracking, Monitoring, and Analytics Software, Consulting Services) Market - Global Forecasts to 2020 3ALT Names Anggie Becorest Senior Vice President of Business Development 2Isis Reports Financial Results and Highlights for First Quarter 2015 2Isis Reports Financial Results and Highlights for First Quarter 2015 3Isis Reports Financial Results and Highlights for First Quarter 2015 4Isis Reports Financial Results and Highlights for First Quarter 2015 5Isis Reports Financial Results and Highlights for First Quarter 2015 6Isis Reports Financial Results and Highlights for First Quarter 2015 7Isis Reports Financial Results and Highlights for First Quarter 2015 8Isis Reports Financial Results and Highlights for First Quarter 2015 9Isis Reports Financial Results and Highlights for First Quarter 2015 10Isis Reports Financial Results and Highlights for First Quarter 2015 11Isis Reports Financial Results and Highlights for First Quarter 2015 12Isis Reports Financial Results and Highlights for First Quarter 2015 13
... Inc. (Nasdaq: CLRT ), a premier technology ... industry, today announced the commercial launch of Mammostrat, a ... of recurrence of breast cancer following surgery and initial ... set of five biomarkers that are able to be ...
... 2010 Stryker Corporation (NYSE: SYK ) announced today ... by declaring a quarterly dividend of $0.18 per share ... close of business on December 31, 2010.   Stryker ... Company to repurchase an additional $500 million of its common stock. ...
Cached Medicine Technology:Clarient Launches Insight® Dx Mammostrat® Breast Cancer Recurrence Test 2Clarient Launches Insight® Dx Mammostrat® Breast Cancer Recurrence Test 3Clarient Launches Insight® Dx Mammostrat® Breast Cancer Recurrence Test 4Stryker Announces Additional $500 Million Share Repurchase Program and Declares a 20% Increase in Quarterly Dividend 2
(Date:5/6/2015)... More and more people are finding success with the ... trainer and nutritionist. This particular diet program has been helping ... weeks or 21 days. , According to author the ... to work on all types of people, regardless of their ... 12 and 23 pounds using the diet, although reports have ...
(Date:5/6/2015)... Radiation Island ” was featured on NewsWatch as part of ... and coolest applications on the market for iOS, Android, and ... conducted the app review and shared with viewers how this ... Touted as one of the best graphics games on iOS, ... obvious because of its rating of 4 ½ stars on ...
(Date:5/5/2015)... It’s not your usual Veterans Affairs outreach ... cars and motorcycles to the 3rd Annual “Crusin Lincoln” Show ... at the Lincoln VA Clinic, 600 S. 70th St. , ... out each other’s rides, but also to talk to employees ... , Staff from the VA Nebraska-Western Iowa Health Care ...
(Date:5/5/2015)... May 05, 2015 With ProPoint: Hand Drawn, ... Final Cut Pro X . With ProPoint: Hand ... space to further more customize each preset all with a ... given up to 90 fully customizable effect presets all within ... curved arrows, straight arrows, underlines, and more. , ProPoint: ...
(Date:5/5/2015)... The Florida Comprehensive Epilepsy and Seizure ... recognized by the National Association of Epilepsy Centers ... role of a specialized epilepsy center is to ... type and seizure syndrome, comprehensive epilepsy education for ... a patient’s diagnosis and surgical treatment or access ...
Breaking Medicine News(10 mins):Health News:Brian Flatt Announces The 3 Week Diet - A Scientifically Proven Diet Plan 2Health News:Top Grossing iPhone Game, Radiation Island, Was Featured on NewsWatch 2Health News:FCPX Plugin Developer Pixel Film Studios release Propoint Hand Drawn 2Health News:Florida Hospital Tampa Epilepsy Program Earns Designation as a Level 4 Epilepsy Center by the National Association of Epilepsy Centers (NAEC) 2
... taking action, study finds , FRIDAY, Feb. 12 ... opening in Canada Friday seem more on the ball ... activity enables elite athletes to see and react to ... new study finds. , Researchers analyzed the reaction time ...
... ... Laser Vision San Diego was recently honored by his patients with Patient’s Choice Recognition for ... San ... Diego was recently honored by his patients with Patient’s Choice Recognition for the year 2009., ...
... ... 2010 first quarter newsletters. In these newsletters focus was put on Immigration Reform, International ... ... 2010 -- International Insurance Group, Inc. (IIG) announced today the release of its 2010 ...
... Feb. 11 Volunteers and staff of the ... former President Bill Clinton upon the reports that ... narrowed coronary arteries.  President Clinton, who underwent quadruple coronary bypass ... to jointly form the Alliance for a Healthier Generation to ...
... , WASHINGTON , Feb. 11 ... commentary published by a working group of the Association of Schools ... 2010 issue of Lancet .  "This framework offers realistic ... role for the future which is essential to maximizing health for ...
... , Cal-EPA signals ,intent to list, plastics chemical ... Feb. 11 The California Environmental Protection Agency signaled intent ... known to cause cancer or birth defects, adding to evidence the ... said BPA "appears to meet the criteria for listing as known ...
Cached Medicine News:Health News:Dr Yaghouti of Global Laser Vision Receives Patient's Choice Award for 2009 2Health News:International Insurance Group, Inc. Releases First Quarter 2010 Newsletters 2Health News:American Heart Association Comment on Hospitalization of President Bill Clinton 2Health News:Global Health Defined as Public Health in a New Lancet Commentary by the Association of Schools of Public Health (ASPH) 2Health News:California Moves Toward Listing BPA as Reproductive Toxin 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: